NASDAQ:VTVT

vTv Therapeutics Stock Forecast, Price & News

$2.71
-0.22 (-7.51 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.69
Now: $2.71
$3.00
50-Day Range
$2.26
MA: $2.71
$3.44
52-Week Range
$1.44
Now: $2.71
$4.75
Volume1.90 million shs
Average Volume6.78 million shs
Market Capitalization$218.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-2
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
vTv Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300
Employees25
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value($0.77) per share

Profitability

Net Income$-13,040,000.00
Net Margins-870.88%

Miscellaneous

Market Cap$218.60 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

VTv Drop on New Product Developments
March 19, 2021 |  baystreet.ca
Aditum Bio Announces Formation of Third Company, Anteris Bio
December 15, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

894th out of 2,024 stocks

Pharmaceutical Preparations Industry

424th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$2.71
-0.22 (-7.51 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

Is vTv Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" vTv Therapeutics stock.
View analyst ratings for vTv Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than vTv Therapeutics?

Wall Street analysts have given vTv Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but vTv Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for vTv Therapeutics
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) released its earnings results on Wednesday, February, 24th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The biotechnology company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $3.30 million.
View vTv Therapeutics' earnings history
.

How has vTv Therapeutics' stock price been impacted by Coronavirus?

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VTVT stock has increased by 11.5% and is now trading at $2.71.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VTVT?

1 brokerages have issued 12 month price objectives for vTv Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate vTv Therapeutics' share price to reach $8.00 in the next year. This suggests a possible upside of 195.2% from the stock's current price.
View analysts' price targets for vTv Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the following people:
  • Ms. Robin E. Abrams, Exec. Chairwoman of the Board (Age 57, Pay $420k)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 64, Pay $684.65k)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 63, Pay $487.18k)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Mr. David M. Lambert III, Sr. VP & Gen. Counsel
  • Dr. Aaron H. Burstein, Sr. VP of Clinical Devel.
  • Dr. Robert C. Andrews, Sr. VP of Chemistry, Pharmaceutical Devel. and Quality
  • Dr. Samuel B. Rollins Ph.D., J.D., Sr. VP of Intellectual Property

Who are some of vTv Therapeutics' key competitors?

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), (CGC), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $2.71.

How much money does vTv Therapeutics make?

vTv Therapeutics has a market capitalization of $218.60 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does vTv Therapeutics have?

vTv Therapeutics employs 25 workers across the globe.

What is vTv Therapeutics' official website?

The official website for vTv Therapeutics is www.vtvtherapeutics.com.

Where are vTv Therapeutics' headquarters?

vTv Therapeutics is headquartered at 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.